NI201900013A - Inhibidor de piridopirimidinona cdk2/4/6 - Google Patents
Inhibidor de piridopirimidinona cdk2/4/6Info
- Publication number
- NI201900013A NI201900013A NI201900013A NI201900013A NI201900013A NI 201900013 A NI201900013 A NI 201900013A NI 201900013 A NI201900013 A NI 201900013A NI 201900013 A NI201900013 A NI 201900013A NI 201900013 A NI201900013 A NI 201900013A
- Authority
- NI
- Nicaragua
- Prior art keywords
- pyridopyrimidinone
- cdk2
- inhibitor
- compounds
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta invención se relaciona con compuestos de la Fórmula general (I), y sales farmacéuticamente aceptables de los mismos, en los cuales R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q y r son como se definenen en la presente, a composiciones farmacéuticas que comprenden tales compuestos y sales, y métodos para utilizar tales compuestos, sales y composiciones para el tratamiento de crecimiento celular anormal, incluyendo cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371602P | 2016-08-15 | 2016-08-15 | |
| US201762533347P | 2017-07-17 | 2017-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201900013A true NI201900013A (es) | 2019-04-08 |
Family
ID=59631834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201900013A NI201900013A (es) | 2016-08-15 | 2019-02-11 | Inhibidor de piridopirimidinona cdk2/4/6 |
Country Status (41)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE055978T2 (hu) * | 2016-08-15 | 2022-01-28 | Pfizer | Piridopirimidinon CDK2/4/6 inhibitorok |
| JP6952747B2 (ja) * | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ |
| JP2020097562A (ja) | 2018-09-25 | 2020-06-25 | ファイザー・インク | ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オンの合成 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| CN113260617A (zh) * | 2019-01-17 | 2021-08-13 | 辉瑞公司 | Cdk抑制剂的结晶形式 |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| US20200316064A1 (en) * | 2019-02-15 | 2020-10-08 | Incyte Corporation | Cyclin-dependent kinase 2 biomarkers and uses thereof |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| MX2021012491A (es) | 2019-04-19 | 2022-01-24 | Pfizer | Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar. |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020240360A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| CN113874036A (zh) | 2019-05-24 | 2021-12-31 | 辉瑞公司 | 使用cdk抑制剂的联合治疗 |
| WO2021014360A1 (en) | 2019-07-23 | 2021-01-28 | Pfizer Inc. | Oral modified release dosage forms |
| AR119765A1 (es) | 2019-08-14 | 2022-01-12 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
| MX2022004390A (es) | 2019-10-11 | 2022-08-08 | Incyte Corp | Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2). |
| EP4046999A4 (en) * | 2019-10-17 | 2023-11-22 | Cisen Pharmaceutical Co., Ltd. | AMINOPYRIMIDINE COMPOUND USED AS TRIPLE INHIBITOR OF CDK2/4/6 |
| MX2022006578A (es) | 2019-12-17 | 2022-07-04 | Pfizer | Anticuerpos especificos para cd47, pd-l1 y sus usos. |
| CN115551856A (zh) * | 2020-02-28 | 2022-12-30 | 重庆复尚源创医药技术有限公司 | 作为cdk2/4/6抑制剂的化合物 |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
| JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置 |
| CN113773315A (zh) * | 2020-06-10 | 2021-12-10 | 无锡佰翱得生物科学有限公司 | 细胞周期蛋白依赖性激酶2（cdk2）高选择性氘代抑制剂 |
| CN115702155A (zh) * | 2020-06-17 | 2023-02-14 | 微境生物医药科技(上海)有限公司 | 新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物 |
| WO2022015670A1 (en) * | 2020-07-14 | 2022-01-20 | Nikang Therapeutics, Inc. | Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2022018667A1 (en) | 2020-07-24 | 2022-01-27 | Pfizer Inc. | Combination therapies using cdk2 and cdc25a inhibitors |
| EP4214202A1 (en) | 2020-09-15 | 2023-07-26 | Pfizer Inc. | Solid forms of a cdk4 inhibitor |
| WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| IL303661A (en) * | 2020-12-22 | 2023-08-01 | Nikang Therapeutics Inc | COMPOUNDS FOR BREAKING CYCLIN-DEPENDENT KINASE 2 THROUGH THE UBIQUITIN PROTEOSOME PATHWAY |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| CN117858879A (zh) * | 2021-01-15 | 2024-04-09 | 南京再明医药有限公司 | Cdk2/4/6抑制剂及其制备方法和应用 |
| CN116456987A (zh) | 2021-06-09 | 2023-07-18 | 郑州同源康医药有限公司 | 用作cdk激酶抑制剂的化合物及其应用 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| WO2023281413A1 (en) | 2021-07-09 | 2023-01-12 | Pfizer Inc. | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer |
| CN116390921A (zh) * | 2021-09-29 | 2023-07-04 | 中国医药研究开发中心有限公司 | 具有细胞周期蛋白依赖性激酶抑制活性的杂环化合物及其制备方法和医药用途 |
| WO2023092104A1 (en) * | 2021-11-18 | 2023-05-25 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
| WO2023141522A2 (en) * | 2022-01-21 | 2023-07-27 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2023249968A1 (en) * | 2022-06-22 | 2023-12-28 | Nikang Therapeutics, Inc. | Bifunctional compounds containing pyrido[2,3-djpyrimidin-7(8h)-one derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
| WO2024039903A2 (en) * | 2022-08-19 | 2024-02-22 | Kymera Therapeutics, Inc. | Cdk2 inhibitors and uses thereof |
| WO2024084364A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Compounds for the treatment of cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| KR20000057228A (ko) | 1996-11-27 | 2000-09-15 | 디. 제이. 우드, 스피겔 알렌 제이 | 축합된 비사이클릭 피리미딘 유도체 |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| ATE391719T1 (de) | 1997-02-05 | 2008-04-15 | Warner Lambert Co | Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| BR0017075A (pt) * | 2000-01-27 | 2002-11-05 | Warner Lambert Co | Derivados de piridopirimidinona para tratamento de doença neurodegenerativa |
| WO2001070741A1 (en) | 2000-03-06 | 2001-09-27 | Warner-Lambert Company | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
| IL156872A0 (en) | 2001-02-12 | 2004-02-08 | Hoffmann La Roche | 6-substituted pyrido-pyrimidines |
| DK1470124T3 (da) * | 2002-01-22 | 2006-04-18 | Warner Lambert Co | 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner |
| US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
| US6951769B2 (en) | 2003-06-04 | 2005-10-04 | Texas Instruments Incorporated | Method for stripping sacrificial layer in MEMS assembly |
| MXPA06000484A (es) | 2003-07-11 | 2006-04-05 | Warner Lambert Co | Sal de isetionato de un inhibidor selectivo de la quinasa 4 dependiente de ciclina. |
| JP2007523151A (ja) | 2004-02-18 | 2007-08-16 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ２−（ピリジン−３−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン |
| US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| US8247408B2 (en) * | 2005-10-07 | 2012-08-21 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer |
| CN101395155A (zh) * | 2005-10-07 | 2009-03-25 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
| MX2009002069A (es) | 2006-09-08 | 2009-03-06 | Pfizer Prod Inc | Sintesis de 2-(piridin-2-ilamino)pirido[2,3-d]pirimidin-7-onas. |
| MEP8009A (en) * | 2006-09-15 | 2011-12-20 | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors | |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| EP2139484B9 (en) * | 2007-04-10 | 2014-06-11 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
| JP5302389B2 (ja) * | 2008-04-29 | 2013-10-02 | エフ．ホフマン−ラ ロシュ アーゲー | Ｊｎｋのピリミジニルピリドンインヒビター |
| WO2010022081A1 (en) | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
| EP2344502A2 (en) | 2008-10-22 | 2011-07-20 | F. Hoffmann-La Roche AG | Pyrimidinyl pyridone inhibitors of jnk |
| EP2694504A4 (en) * | 2011-04-08 | 2014-08-27 | Afraxis Holdings Inc | 8-ETHYL-6 (ARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF DISEASES AFFECTING THE NERVOUS SYSTEM AND FOR THE TREATMENT OF CANCER |
| TW201311683A (zh) * | 2011-04-29 | 2013-03-16 | Exelixis Inc | 使用吡啶并嘧啶酮ｐｉ３ｋ／ｍｔｏｒ抑制劑治療淋巴瘤之方法 |
| TW201306842A (zh) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| US9718821B2 (en) * | 2012-02-23 | 2017-08-01 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| PL3431475T3 (pl) | 2013-02-21 | 2021-09-13 | Pfizer Inc. | Stałe postacie selektywnego inhibitora CDK4/6 |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| WO2015084936A1 (en) * | 2013-12-04 | 2015-06-11 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| US9760610B2 (en) | 2014-07-31 | 2017-09-12 | Linkedin Corporation | Personalized search using searcher features |
| CZ201589A3 (cs) * | 2015-02-11 | 2016-08-24 | Zentiva, K.S. | Pevné formy soli Palbociclibu |
| HUE055978T2 (hu) * | 2016-08-15 | 2022-01-28 | Pfizer | Piridopirimidinon CDK2/4/6 inhibitorok |
-
2017
- 2017-07-31 HU HUE17752493A patent/HUE055978T2/hu unknown
- 2017-07-31 TN TNP/2019/000039A patent/TN2019000039A1/en unknown
- 2017-07-31 CN CN202210092651.2A patent/CN114394966A/zh active Pending
- 2017-07-31 KR KR1020197007466A patent/KR102236605B1/ko active IP Right Grant
- 2017-07-31 CA CA2975033A patent/CA2975033C/en active Active
- 2017-07-31 MX MX2019001849A patent/MX2019001849A/es unknown
- 2017-07-31 GE GEAP201714998A patent/GEP20217234B/en unknown
- 2017-07-31 JP JP2019507917A patent/JP6563623B1/ja active Active
- 2017-07-31 EP EP17752493.1A patent/EP3497103B1/en active Active
- 2017-07-31 MA MA45920A patent/MA45920B1/fr unknown
- 2017-07-31 CR CR20190062A patent/CR20190062A/es unknown
- 2017-07-31 CU CU2019000010A patent/CU24522B1/es unknown
- 2017-07-31 US US15/664,265 patent/US10233188B2/en active Active
- 2017-07-31 WO PCT/IB2017/054655 patent/WO2018033815A1/en active Application Filing
- 2017-07-31 SI SI201730793T patent/SI3497103T1/sl unknown
- 2017-07-31 SG SG11201900799XA patent/SG11201900799XA/en unknown
- 2017-07-31 BR BR112019002610A patent/BR112019002610A2/pt active Search and Examination
- 2017-07-31 LT LTEP17752493.1T patent/LT3497103T/lt unknown
- 2017-07-31 RS RS20210691A patent/RS61934B1/sr unknown
- 2017-07-31 CN CN201780063655.5A patent/CN109803968A/zh active Pending
- 2017-07-31 PT PT177524931T patent/PT3497103T/pt unknown
- 2017-07-31 UA UAA201900905A patent/UA124804C2/uk unknown
- 2017-07-31 MD MDE20190682T patent/MD3497103T2/ro unknown
- 2017-07-31 PL PL17752493T patent/PL3497103T3/pl unknown
- 2017-07-31 RU RU2019104087A patent/RU2726115C1/ru active
- 2017-07-31 ES ES17752493T patent/ES2876411T3/es active Active
- 2017-07-31 PE PE2019000359A patent/PE20190475A1/es unknown
- 2017-07-31 AU AU2017311645A patent/AU2017311645B2/en active Active
- 2017-07-31 DK DK17752493.1T patent/DK3497103T3/da active
- 2017-08-02 TW TW106126113A patent/TWI663169B/zh active
- 2017-08-04 UY UY0001037352A patent/UY37352A/es not_active Application Discontinuation
-
2019
- 2019-01-17 US US16/251,032 patent/US10800783B2/en active Active
- 2019-02-04 ZA ZA2019/00716A patent/ZA201900716B/en unknown
- 2019-02-06 IL IL264687A patent/IL264687B/en active IP Right Grant
- 2019-02-11 NI NI201900013A patent/NI201900013A/es unknown
- 2019-02-12 CO CONC2019/0001240A patent/CO2019001240A2/es unknown
- 2019-02-12 CL CL2019000368A patent/CL2019000368A1/es unknown
- 2019-02-14 EC ECSENADI201911216A patent/ECSP19011216A/es unknown
- 2019-02-14 DO DO2019000030A patent/DOP2019000030A/es unknown
- 2019-02-15 PH PH12019500329A patent/PH12019500329A1/en unknown
- 2019-02-15 SV SV2019005836A patent/SV2019005836A/es unknown
-
2020
- 2020-08-27 US US17/005,233 patent/US11396512B2/en active Active
-
2021
- 2021-06-01 HR HRP20210871TT patent/HRP20210871T1/hr unknown
- 2021-06-07 CY CY20211100495T patent/CY1124206T1/el unknown
-
2022
- 2022-06-15 US US17/841,138 patent/US20220324872A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201900013A (es) | Inhibidor de piridopirimidinona cdk2/4/6 | |
| CL2020002748A1 (es) | Inhibidores de cinasa dependientes de ciclina | |
| UY38553A (es) | Inhibidores de cdk2 | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| UY38471A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| ECSP16016726A (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
| CU20180152A7 (es) | Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| UY37205A (es) | Inhibidores de bromodominios | |
| CO2019005534A2 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| ECSP18056196A (es) | Derivados de indano | |
| CU20140033A7 (es) | Derivados de pirrolopirimidina y purina | |
| ECSP17003149A (es) | Compuestos de dihidroisoquinolinona sustituida |